



Published in final edited form as:

Prev Med. 2019 March ; 120: 119–125. doi:10.1016/j.ypmed.2019.01.014.

A Cost-Effectiveness Analysis of a Colorectal Cancer Screening Program in Safety Net Clinics

Richard T. Meenan, PhD, MPH, MBA^{a,*}, Gloria D. Coronado, PhD^a, Amanda Petrik, MS^a, and Beverly B. Green, MD, MPH^b

^aKaiser Permanente Center for Health Research, 3800 N Interstate Ave, Portland, OR, 97227, USA

^bKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA, USA

Abstract

STOP CRC is a cluster-randomized pragmatic study of a colorectal cancer (CRC) screening program within eight federally-qualified health centers (FQHCs) in Oregon and California promoting fecal immunochemical testing (FIT) with appropriate colonoscopy follow-up. Results are presented of a cost-effectiveness analysis of STOP CRC. Organization staff completed activity-based costing spreadsheets, assigning labor hours by intervention activity and job-specific wage rates. Non-labor costs were from study data. Data were collected over February 2014–February 2016; analyses were performed in 2016–2017. Incremental cost-effectiveness ratios (ICERs) using completed FITs adjusted for number of screening-eligible patients (SEPs), as the effectiveness measure were calculated overall and by organization. Intervention delivery costs totaled \$305K across eight organizations (range: \$10.2K–\$110K). Overall delivery cost per SEP was \$14.43 (range: \$10.37–\$19.10). The largest cost category across organizations was implementation, specifically mailing preparation. The overall ICER was \$483 per SEP-adjusted completed FIT (range: \$96–\$1,021 among organizations with positive effectiveness). Lagged data accounting for implementation delay produced comparable results. The costs of colonoscopies following abnormal FITs decreased the overall ICER to \$409 because usual care clinics generated more such colonoscopies than intervention clinics. Using lagged data, follow-up colonoscopies increase the ICER by 4.3% to \$460. Results indicate the complex implications for cost-effectiveness of implementing standard CRC screening within a pragmatic setting involving FQHCs with varied patient populations, clinical structures, and resources. Performance variation across organizations emphasizes the need for future evaluations that inform the introduction of efficient CRC screening to underserved populations.

*Corresponding author: Richard.Meenan@kpchr.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

INTRODUCTION

Over the past two decades, colorectal cancer (CRC) incidence has declined in the United States, yet CRC remains the third most common cancer and the second most common cause of death, with over 140,000 new cases and over 50,000 deaths expected in 2018 (Siegel, Miller, & Jemal, 2018). It has been known for at least this long that effective CRC screening can reduce incidence and mortality, as reflected in US Preventive Services Task Force recommendations for CRC screening among adults aged 50–75. However, in 2015 only 63% of adults aged 50 and older were up-to-date on CRC screening (American Cancer Society, 2017), a rate below the targets of the National Colorectal Cancer Roundtable (80%) (National Colorectal Cancer Roundtable, 2018) and Healthy People 2020 (70.5%) (Office of Disease Prevention and Health Promotion, 2017). Despite recent improvement (30.2% in 2012 to 39.9% in 2016), CRC screening rates among adults served by federally qualified health centers (FQHCs) remain well below those of non-FQHC populations (National Colorectal Cancer Roundtable, 2018). Fecal immunochemical testing (FIT) may be a low-cost and effective population-based screening option in the FQHC context when combined with colonoscopy follow-up for positive FITs.

We conducted the Strategies and Opportunities to STOP Colon Cancer in Priority Populations (STOP CRC) study to evaluate the effectiveness of a mailed FIT intervention delivered by clinic staff at FQHCs. This cluster-randomized pragmatic study provided 13 clinics with electronic health record (EHR) tools to identify and contact patients who were due for screening; trained clinic staff to use the tools; and compared results to 13 clinics practicing usual care. This paper presents the results of a cost-effectiveness analysis of the STOP CRC intervention.

METHODS

Study design, recruitment details, and results have been published previously (Coronado et al., 2018; Coronado et al., 2016; Coronado, Vollmer, Petrik, Aguirre, et al., 2014; Coronado, Vollmer, Petrik, Taplin, et al., 2014; Coury et al., 2017; Petrik et al., 2016). The study was approved by the Institutional Review Board of Kaiser Permanente Northwest (Protocol # 4364), with ceding agreements from Kaiser Permanente Washington Health Research Institute and OCHIN (formerly Oregon Community Health Information Network).

Setting and Participants

The study included seven FQHCs representing 24 clinics and two clinics affiliated with an academic medical center, serving similar low-income populations. Participating health centers were willing to randomize clinics and to use a single fecal test across all participating clinics, had an electronic interface with the lab that processed the FIT kits, and had sufficient follow-up colonoscopy capacity (G. D. Coronado et al., 2016).

Participating clinics were randomized to either usual care ($n = 13$) or an electronic health record (EHR)-embedded intervention ($n = 13$) described below. Eligible adults were aged 50–74, had a clinic visit during the 12 months prior to accrual, and were due for CRC screening based on having no EHR evidence of completing a fecal test during the past 11

months, a flexible sigmoidoscopy during the past 4 years, or a colonoscopy during the past 9 years; and no evidence of a fecal test order in the past 6 months or a sigmoidoscopy or colonoscopy referral in the past year. Adults were excluded with evidence of a limited set of health conditions (e.g. colorectal cancer, colon disease, end-stage renal failure). Patients were identified using real-time EHR tools updated daily.

Usual Care

Usual care clinics continued standard CRC screening processes, which varied by health center and typically involved providing information and ordering screening tests during routine clinical encounters. Usual care clinics were offered training and intervention materials at the end of the follow-up period. Activity in usual care (and intervention) clinics may have been influenced by changes in the external environment during the study period, which saw secular growth in CRC screening within FQHCs, both nationally and in study clinics. In particular, the Affordable Care Act's Medicaid expansion removed a critical structural barrier to CRC screening by offering insurance to many previously uninsured Oregonians and Californians who were age-eligible for CRC screening. Also, in 2014 CRC screening became an incentivized metric for Oregon's Coordinated Care Organizations that administer services for Medicaid enrollees.

Intervention

The STOP CRC intervention consisted of an automated data-driven, EHR-embedded program (Epic© EHR software [version 2010; Verona, WI] Reporting Workbench) for mailing FIT kits to patients due for CRC screening. Reporting Workbench users work with customized templates to produce "real-time" reports on lists of patients, including orders, appointments, or diagnoses. Tools were designed so that eligible patients could be sent a letter introducing the study (available in English, Spanish, Russian, and Mandarin Chinese) with a number to call if they had clinical concerns, had been previously screened, or simply declined participation. Clinic staff were trained on how to mail eligible patients FIT kits, including pictorial instructions and return postage (G. D. Coronado, Sanchez, et al., 2014; Petrik et al., 2016). The EHR tools generated lists of patients not reported as completing the kit, to whom a single reminder letter could be mailed.

Reports at participating clinics were updated nightly through EHR data on eligibility, mailing, and FIT completion status, with completion representing processing and reporting of a returned FIT. Four to six months after clinic staff training, a plan-do-study-act (PDSA) improvement cycle was facilitated during which, participating clinics identified strategies to enhance reach or effectiveness (Coury et al., 2017). The STOP CRC intervention had three basic elements (introductory letter, FIT kit, and reminder letter); however, organizations tailored implementation to their individual systems.

Trial outcomes

The primary study outcome was clinic-level proportions of eligible adults during the accrual interval (February 2014–February 2015) who completed FIT testing within 12 months, or through August 2015 (after which, study tools were made available to usual care clinics). A secondary outcome was the clinic-level proportion of participants receiving any CRC

screening (FIT, sigmoidoscopy or colonoscopy) during the evaluation interval. Implementation was calculated as the clinic-level proportion of participants mailed an introductory letter and who subsequently ordered a FIT during the evaluation interval. This allowed mailed FITs to be distinguished from those distributed in-clinic.

Lagged analysis

While the planned analysis included all individuals accrued after EHR tools were provided to clinics on February 4, 2014 (the date of randomization), no clinic began printing letters until at least June 2014; some did not begin until spring 2015. This delay in implementation allowed clinics to address site-specific issues, such as conducting staff training in EHR tools, obtaining supplies, and dealing with staff turnover. To account for this delay, analyses were repeated using a “lagged” dataset that included only individuals accrued between June 4, 2014 and February 3, 2015. As with the primary dataset, outcomes were assessed through August 3, 2015, after which intervention materials were made available to usual care clinics.

Economic outcome

The primary analytic outcome is an incremental cost-effectiveness ratio (ICER), the additional cost per outcome for an intervention that improves outcomes over a reference strategy (here, usual care). The ICER was calculated as $(\text{cost}_i - \text{cost}_{uc})/(\text{effect}_i - \text{effect}_{uc})$, where i = intervention and uc = usual care. For tractability as well as to account for differences in clinic size across organizations, the number of completed FITs adjusted for number of screening-eligible patients (SEPs) was used as the effect measure, rather than the proportion of such adults with completed FITs. We calculated the ICER overall as well as for each participating organization using both the primary and lagged trial outcomes.

Costs

Intervention delivery costs were defined as the value of resources used to develop, implement, and maintain the screening intervention over the trial period and were measured from the organizational perspective (Basu, 2016). Research-related costs were excluded. Intervention components were classified as labor (e.g., mailing activities) or non-labor (e.g., FIT kits).

To capture labor resources, the research team developed a series of spreadsheets for clinic staff to complete. The spreadsheets were organized in an activity-based costing format (Lee, Austin, & Pronovost, 2016), disaggregating the STOP CRC intervention into a series of activities classified in a few categories: data organization and management, staff training, implementation process, program management, test processing, and delivery support (Table 1). Program management was defined as billing adjustments, PDSA meetings, and provider engagement meetings. Intervention activities reported by the clinics were based on the project workplan and were reviewed by the research team for validity and completeness. The cost of colonoscopy with polypectomy or biopsy is adapted from Naber et al., 2018 and reported in 2018 US dollars (\$1,897) (Naber et al., 2018; US Bureau of Labor Statistics, 2018). Costs are reported in 2018 US dollars and are not discounted because of the limited time horizon. Confidence intervals are calculated applying Fieller’s theorem (Willan & O’Brien, 1996).

TRIAL RESULTS

Primary dataset

Table 2 lists the numbers of screened participants and their proportions of SEPs by organization. Overall, intervention clinics obtained completed FITs from 14.3% of their SEPs (3,003/21,134), compared to 10.7% of SEPs (2,146/20,059) in usual care clinics. Both arms exhibited considerable variability in the proportion of completed FITs; proportions among intervention clinics ranged from 4.3% (101/2,352) to 22.9% (403/1,761) and from 2.7% (23/840) to 21.3% (427/2,004) among usual care clinics. Also, within three organizations the proportion of returned FITs among SEPs in their intervention clinics was lower than in their usual care clinics, with differences ranging from -2.9% to -7.4%.

Lagged dataset

Overall, intervention clinics obtained completed FITs from 17.5% of their SEPs (2,778/15,763), compared to 12.7% of SEPs (1,972/14,904) in usual care clinics. Both arms exhibited considerable variability in the proportion of completed FITs; proportions among intervention clinics ranged from 7.2% (133/1,851) to 27.1% (377/1,392) and from 3.4% (23/674) to 21.9% (344/1,571) among usual care clinics. Also, within three organizations the proportion of completed FITs among SEPs in their intervention clinics was lower than in their usual care clinics, with differences ranging from -2.0% to -11.7%.

Economic Results

Table 3 presents delivery costs and baseline ICERs, both in total and by organization. Delivery costs totaled \$305K, ranging from \$10.2K to \$110K across organizations. Overall delivery cost per SEP was \$14.43 and varied from \$10.37 (HC6) to \$19.10 (HC2) across organizations. The overall ICER across all eight organizations was \$483 per SEP-adjusted completed FIT; however, this overall value includes three organizations for which their intervention clinics generated fewer SEP-adjusted completed FITs than their usual care clinics. (One organization reported fewer absolute, but a higher proportion of, FITs in its intervention clinics.) For the five organizations reporting more SEP-adjusted completed FITs in their intervention clinics, ICERs ranged from \$96 to \$1,021 per SEP-adjusted completed FIT. Using the lagged results (Table 4), three organizations produced fewer SEP-adjusted completed FITs in intervention clinics than in usual care clinics. The overall ICER was \$441 per SEP-adjusted completed FIT, although organization-level ICERs ranged from \$97 to \$534.

Per-clinic delivery costs, averaging \$23.3K across organizations, ranged from \$8.4K (HC8) to \$36.7K (HC2). Per-clinic delivery costs for HC2 were somewhat higher than for other organizations because HC2 reported 300 hours of full-time staff training in preparation for intervention start-up, which were substantially higher than for any other organization. Figure 1 presents STOP CRC's per-clinic activity categories by organization. Regardless of the magnitude of overall costs, the largest reported cost category for each organization was implementation, specifically mailing preparation, which included printing letters, affixing labels on tubes or cards and envelopes, and placing lab orders.

The ICERs reported earlier do not include costs of follow-up colonoscopy for abnormal FITs; however, potential implementers of a screening program such as STOP CRC are presumably interested in its implications for limited colonoscopy resources. Table 3 also presents primary data on the number of SEP-adjusted completed FITs per organization that were judged abnormal and the number receiving follow-up colonoscopy. This is a conservative cost estimate for colonoscopy because many colonoscopies do not involve polypectomy or biopsy. Adding the cost of colonoscopies for abnormal FITs decreases the overall incremental cost per returned FIT to \$409. This counterintuitive result arises because 45.3% of abnormal FITs in usual care clinics were followed up with colonoscopy versus 35.7% in intervention clinics. However, this phenomenon is not observed in the lagged data (Table 4); follow-up colonoscopies increase the cost per SEP-adjusted completed FIT by 4.3% to \$460.

DISCUSSION

Although the total cost of delivering the STOP CRC intervention varied substantially (\$10.1K-\$110K) across organizations, the delivery cost per SEP varied much less (\$10.37-\$19.10). It should be noted that HC2 is a county-wide health system with a workforce and patient population, both significantly larger than other participating organizations. The largest cost categories were related to disseminating the FIT to screening-eligible patients and general data management, involving developing program tracking reports for use in extant electronic data systems, and staff training in use of the reports, which were new to the clinics. They have subsequently been applied to other population-based care efforts, and less training may be required if staff has experience with the tools. Apart from one organization that devoted substantial resources to staff training, implementation was the most resource-intensive activity for all organizations. The resource burden of test processing was minimal.

As we previously report, STOP CRC achieved a 21% return rate on mailed FITs (Coronado et al., 2018), consistent with many previous evaluations of mailed FIT outreach (Goldman et al., 2015; Green, Anderson, et al., 2017; Green, Fuller, et al., 2017; Gupta et al., 2013; Levy, Xu, Daly, & Ely, 2013; Singal et al., 2016). As a pragmatic study, STOP CRC relied on clinic staff to deliver the intervention, and levels of intervention delivery varied substantially by clinic. Only one-third of eligible patients were mailed a FIT, with clinic-level performance ranging from 3% to 68% (Coronado et al., 2018). The STOP CRC primary outcomes evaluation relied on difference between intervention and usual care in clinic-level proportions of completed FITs, which was much lower than the FIT return rate (3.4% vs. 21%). These results suggest that additional resources directed towards staff training in mailed FIT outreach could improve the cost-effectiveness of an intervention such as STOP CRC.

The study-wide ICER for STOP CRC of \$483 per SEP-adjusted completed FIT (\$441 in lagged data) is somewhat higher than those of other CRC screening outreach studies (Lewis, Brenner, McGriffith, & Pignone, 2008; Tangka et al., 2013; Liss et al., 2016; Sequist, Franz, & Ayanian, 2010; Meenan et al., 2015). However, each of these studies differ from ours in significant ways, ranging from multi-modality (Lewis) to clinical cost assessment (Tangka) to simulation-based budget impact analysis (Liss) to a multispecialty group practice

(Sequist) to an integrated health care system in which all patients had insurance, with colonoscopy costs all or mostly covered and with easy access to endoscopy services (Meenan). This differs from community clinics, in which screening colonoscopies are less common because of less insurance coverage and limited access (Bass et al., 2011; Davis, Morris, Rademaker, Ferguson, & Arnold, 2017; Ferreira et al., 2005; Robinson et al., 2011).

To our knowledge, this is the first cost-effectiveness analysis of a pragmatic CRC screening study conducted across a variety of FQHCs. The overall ICERs mask considerable heterogeneity in performance across the eight participating organizations. In both primary and lagged data, in three organizations the intervention did not increase the number of SEP-adjusted completed FITs over usual care. In the other organizations, the ICERs varied widely. This was in part due to the pragmatic aspects of the STOP CRC trial in which organizations implemented the intervention in a manner appropriate for their system and resources. The study's pragmatic nature likely resulted in higher costs for clinic staff to conduct data cleaning and training, especially in smaller clinics without extensive organizational infrastructure.

The pragmatic design may also have contributed to our observation, within the primary dataset, that the proportion of abnormal FITs receiving follow-up colonoscopy was higher in usual care clinics than in intervention clinics, which decreased the overall incremental cost per returned FIT. This could reflect small-sample randomness or could reflect the fact that usual care clinics primarily distributed FIT kits during clinical encounters; such kits typically received better follow-up than mailed kits. An abnormal result in usual care would prompt a provider referral following a visit in which the kit was distributed. A mailed FIT may have had an abnormal result, but a more recent colonoscopy could have been found in the patient's record, co-morbidities (e.g., cancer) that made colonoscopy follow-up inappropriate, or the patient may simply have been lost to follow-up.

Despite the heterogeneous results across organizations, a few lessons from our experience may be useful to future adopters. First, since mailing activities represent the largest portion of cost across organizations, dissemination methods that can be integrated well into regular staff activities would enhance the efficiency of programs such as STOP CRC. This is especially salient, given the varied ability of clinics to reach screening-eligible patients. As noted earlier, screening uptake among contacted patients was comparable to many previous studies, so staff training in efficient dissemination methods could yield significant benefits in terms of more screened patients. Second, it is important to exploit extant programs whenever possible, e.g., use existing quality improvement staff, if available, to enhance consistent and efficient program delivery. Third, "scrubbing" data records (i.e., removing or amending incorrect, incomplete, or duplicate data) is expensive. Processes that generate correct and current data the first time will facilitate efficient identification of relevant screening events. Fourth, clinics will benefit from the continued rollout of EHR systems within FQHCs and related tools, such as Reporting Workbench. As these systems become more prevalent, and clinic staff become more experienced users, challenges, for example, of data capture (e.g., colonoscopy underreporting, verification of FIT mailing) should gradually lessen, reducing costs. This is not to ignore the importance of external factors such as staff turnover and conflicting management priorities, but simply to acknowledge the potential for improved

information flows that will enhance the success of programs such as STOP CRC. Fifth, always be in a “learning” mode; clinics should use documented evidence and the experience of other systems to inform their ongoing program activities. To that end, regular meetings with other implementing clinics can help participants learn from each other’s successes and failures.

This analysis has several limitations, particularly its reliance on retrospective questionnaire responses from implementing staff. Although this is appropriate for micro-level data collection (Frick, 2009), such an approach has inherent recall issues. We strove to minimize these issues by focusing on key informants at each organization and attempting to facilitate consistent understanding of terms and concepts. However, the heterogeneity of experiences and ability to recall events, magnified by high staff turnover at some sites, complicated data collection. Whenever possible, we re-contacted our informants to clarify responses, but considerable ambiguity remains. Future economic research should explore new methods of extracting micro-level implementation data vital to understanding the economics of screening programs. Data collection methods that are not perceived by clinic staff as intrusions into ongoing patient care are especially valuable. A checklist for the conduct and reporting of micro-costing studies may be helpful in this regard (Ruger & Reiff, 2016). In addition, “time-driven” activity-based costing (TDABC), a modified form of the standard ABC methodology applied in this study, has been described as a micro-costing approach well suited to accommodate complex health care cost accounting (Kaplan & Anderson, 2004; Kaplan & Porter, 2011). Standard ABC is considered a resource-intensive approach to data collection, which can inhibit its use. TDABC is intended to maintain the validity of cost data while reducing the resources needed to acquire them. TDABC requires only two key parameters: the capacity cost rate (the cost of capacity-supplying resources divided by their practical, not theoretical, capacity), and the time required to perform service delivery activities. To date, TDABC has been used primarily to analyze hospital and clinic services (Keel, Savage, Rafiq, & Mazzocato, 2017), but its utility in facilitating evaluation of FQHC screening programs such as STOP CRC should also be explored.

In addition, program-level data did not distinguish between costs of screening and diagnostic colonoscopy for each organization, which complicates understanding the true intervention effects in terms of improving CRC screening rates. Improved organization-level data systems will mitigate this issue. Also, our implementation cost estimates are based on eight organizations. Finally, cross-organizational differences in patient population, management commitment to STOP CRC, resource availability, and other latent factors may well contribute to our reported cost differences.

CONCLUSION

Our results indicate the implications for cost-effectiveness of implementing a standard CRC screening intervention within a pragmatic trial setting involving multiple FQHCs with varied patient populations, clinical structures, and resource availability. The variation in performance across organizations serves to emphasize the need for future similar evaluations that can contribute to our knowledge of how to introduce such screening programs to underserved populations most effectively and efficiently.

ACKNOWLEDGMENTS

We gratefully acknowledge the contributions of Bill Vollmer, Jennifer Schneider, Jennifer Rivelli, and Sacha Reich (Center for Health Research, Kaiser Permanente Northwest). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Meenan was primarily responsible for data analysis and paper writing. Ms. Petrik contributed to data generation and analysis as well as paper editing. Drs. Coronado and Green contributed to study design, data analysis and paper editing. The STOP CRC trial is registered at [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01742065) (NCT01742065). No financial disclosures were reported by the authors of this paper.

FUNDING

This work was supported by the National Cancer Institute of the National Institutes of Health (UH3CA188640).

REFERENCES

- American Cancer Society. (2017). Colorectal Cancer Facts & Figures 2017–2019 Atlanta: American Cancer Society Retrieved from <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2017-2019.pdf>. Accessed 7 Aug 2018
- Bass SB, Gordon TF, Ruzek SB, Wolak C, Ward S, Paranjape A, ... Ruggieri DG (2011). Perceptions of colorectal cancer screening in urban African American clinic patients: differences by gender and screening status. *Journal of Cancer Education*, 26(1), 121–128. doi:10.1007/s13187-010-0123-9 [PubMed: 20443096]
- Basu A (2016). Estimating Costs and Valuations of Non-Health Benefits in Cost-Effectiveness Analysis. In Neumann PJ, Sanders GD, Russell LB, Siegel JE, & Ganiats TG (Eds.), *Cost-effectiveness in Health and Medicine* (2nd ed.). Oxford: Oxford University Press.
- Coronado GD, Petrik AF, Vollmer WM, Taplin SH, Keast EM, Fields SC, & Green BB (2018). Effectiveness of a mailed colorectal cancer screening outreach program in community health clinics: The STOP CRC cluster randomized clinical trial. *JAMA Internal Medicine* doi:doi:10.1001/jamainternmed.2018.3629
- Coronado GD, Retecki S, Schneider J, Taplin SH, Burdick T, & Green BB (2016). Recruiting community health centers into pragmatic research: Findings from STOP CRC. *Clinical Trials*, 13(2), 214–222. doi:10.1177/1740774515608122 [PubMed: 26419905]
- Coronado GD, Sanchez J, Petrik A, Kapka T, DeVoe J, & Green B (2014). Advantages of wordless instructions on how to complete a fecal immunochemical test: Lessons from patient advisory council members of a federally qualified health center. *Journal of Cancer Education*, 29(1), 86–90. doi:10.1007/s13187-013-0551-4 [PubMed: 24057692]
- Coronado GD, Vollmer WM, Petrik A, Aguirre J, Kapka T, Devoe J, ... Green B (2014). Strategies and opportunities to STOP colon cancer in priority populations: Pragmatic pilot study design and outcomes. *BMC Cancer*, 14, 55. doi:10.1186/1471-2407-14-55 [PubMed: 24571550]
- Coronado GD, Vollmer WM, Petrik A, Taplin SH, Burdick TE, Meenan RT, & Green BB (2014). Strategies and opportunities to STOP Colon Cancer in priority populations: Design of a cluster-randomized pragmatic trial. *Contemporary Clinical Trials*, 38(2), 344–349. doi:10.1016/j.cct.2014.06.006 [PubMed: 24937017]
- Coury J, Schneider JL, Rivelli JS, Petrik AF, Seibel E, D'Agostini B, ... Coronado GD (2017). Applying the Plan-Do-Study-Act (PDSA) approach to a large pragmatic study involving safety net clinics. *BMC Health Services Research*, 17(1), 411. doi:10.1186/s12913-017-2364-3 [PubMed: 28629348]
- Davis T, Morris J, Rademaker A, Ferguson L, & Arnold C (2017). Barriers and facilitators to colorectal cancer screening among rural women in community clinics by health literacy. *Journal of Women's Health, Issues, and Care*, 6(6). doi:10.4172/2325-9795.1000292
- Ferreira MR, Dolan NC, Fitzgibbon ML, Davis TC, Gorby N, Ladewski L, ... Bennett CL (2005). Health care provider-directed intervention to increase colorectal cancer screening among veterans: results of a randomized controlled trial. *Journal of Clinical Oncology*, 23(7), 1548–1554. doi: 10.1200/jco.2005.07.049 [PubMed: 15735130]

- Frick KD (2009). Micro-Costing Quantity Data Collection Methods. *Medical Care*, 47(7 Suppl 1), S76–S81. doi:10.1097/MLR.0b013e31819bc064 [PubMed: 19536026]
- Goldman SN, Liss DT, Brown T, Lee JY, Buchanan DR, Balsley K, ... Baker DW (2015). Comparative effectiveness of multifaceted outreach to initiate colorectal cancer screening in community health centers: A Randomized controlled trial. *Journal of General Internal Medicine*, 30(8), 1178–1184. doi:10.1007/s11606-015-3234-5 [PubMed: 25814264]
- Green BB, Anderson ML, Cook AJ, Chubak J, Fuller S, Meenan RT, & Vernon SW (2017). A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial. *Cancer* doi:10.1002/cncr.30908
- Green BB, Fuller S, Anderson ML, Mahoney C, Mendy P, & Powell SL (2017). A quality improvement initiative to increase colorectal cancer (CRC) screening: Collaboration between a primary care clinic and research team. *Journal of Family Medicine*, 4(3). doi:10.26420/jfammed.2017.1115
- Gupta S, Halm EA, Rockey DC, Hammons M, Koch M, Carter E, ... Skinner CS (2013). Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: A randomized clinical trial. *JAMA Internal Medicine*, 173(18), 1725–1732. [PubMed: 23921906]
- Kaplan RS, & Anderson SR (2004). Time-driven activity-based costing. *Harvard Business Review*, (11 2004). Retrieved from <https://hbr.org/2004/11/time-driven-activity-based-costing>. Accessed 7 Aug 2018.
- Kaplan RS, & Porter ME (2011). The Big Idea: How to solve the cost crisis in health care. *Harvard Business Review*, (9 2011). Retrieved from <https://hbr.org/2011/09/how-to-solve-the-cost-crisis-in-health-care>. Accessed 7 Aug 2018.
- Keel G, Savage C, Rafiq M, & Mazzocato P (2017). Time-driven activity-based costing in health care: A systematic review of the literature. *Health Policy*, 121(7), 755–763. doi:10.1016/j.healthpol.2017.04.013 [PubMed: 28535996]
- Lee KK, Austin J, & Pronovost PJ (2016). Developing a measure of value in health care. *Value in Health*, 19(4), 323–325. doi:10.1016/j.jval.2014.12.009 [PubMed: 27325323]
- Levy BT, Xu Y, Daly JM, & Ely JW (2013). A randomized controlled trial to improve colon cancer screening in rural family medicine: an Iowa Research Network (IRENE) study. *Journal of the American Board of Family Medicine*, 26(5), 486–497. doi:10.3122/jabfm.2013.05.130041 [PubMed: 24004700]
- Lewis CL, Brenner AT, McGriffith JM, & Pignone MP (2008). The uptake and effect of a mailed multi-modal colon cancer screening intervention: A pilot controlled trial. *Implementation Science*, 3(32). doi:10.1186/1748-5908-3-32
- Liss D, French D, Buchanan D, Brown T, Magner B, Kollar S, & Baker D (2016). Outreach for annual colorectal cancer screening: A budget impact analysis for community health centers. *American Journal of Preventive Medicine*, 50(2), 54–61. doi:10.1016/j.amepre.2015.07.003
- Meenan RT, Anderson ML, Chubak J, Vernon SW, Fuller S, Wang CY, & Green BB (2015). An economic evaluation of colorectal cancer screening in primary care practice. *American Journal of Preventive Medicine*, 48(6), 714–721. doi:10.1016/j.amepre.2014.12.016 [PubMed: 25998922]
- Naber SK, Kuntz KM, Henrikson NB, Williams MS, Calonge N, Goddard KA, ... Landsdorp-Vogelaar I (2018). Cost effectiveness of age-specific screening intervals for people with family histories of colorectal cancer. *Gastroenterology*, 154(1), 105–116.e120. doi:10.1053/j.gastro.2017.09.021 [PubMed: 28964749]
- National Colorectal Cancer Roundtable. (2018). CRC screening rates reach 39.9% in FQHCs in 2016 Retrieved from <http://nccrt.org/2016-uds-rates/>. Accessed 12 February 2018.
- Office of Disease Prevention and Health Promotion. (2017). Clinical Preventive Services: Colorectal Cancer Screening (C-16) Retrieved from <https://www.healthypeople.gov/2020/leading-health-indicators/2020-lhi-topics/Clinical-Preventive-Services/data>. Accessed 7 Aug 2018.
- Petrik AF, Green BB, Vollmer WM, Le T, Bachman B, Keast E, Coronado GD (2016). The validation of electronic health records in accurately identifying patients eligible for colorectal

cancer screening in safety net clinics. *Family Practice*, 33(6), 639–643. doi:10.1093/fampra/cmw065 [PubMed: 27471224]

Robinson CM, Cassells AN, Greene MA, Beach ML, Tobin JN, & Dietrich AJ (2011). Barriers to colorectal cancer screening among publicly insured urban women: No knowledge of tests and no clinician recommendation. *Journal of the National Medical Association*, 103(8), 746–753. [PubMed: 22046852]

Ruger J, & Reiff M (2016). A checklist for the conduct, reporting, and appraisal of microcosting studies in health care: Protocol development. *JMIR Research Protocols*, 5(4), e195. doi:10.2196/resprot.6263 [PubMed: 27707687]

Sequist TD, Franz C, & Ayanian JZ (2010). Cost-effectiveness of patient mailings to promote colorectal cancer screening. *Medical Care*, 48(6), 553–557. doi:10.1097/MLR.0b013e3181dbd8eb [PubMed: 20473196]

Siegel RL, Miller K, D., & Jemal A (2018). Cancer statistics, 2018. *CA Cancer J Clin*, 68(1), 7–30. doi:10.3322/caac.21442 [PubMed: 29313949]

Singal AG, Gupta S, Tiro JA, Skinner CS, McCallister K, Sanders JM, ... Halm EA (2016). Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system. *Cancer*, 122(3), 456–463. doi:10.1002/cncr.29770 [PubMed: 26535565]

Tangka FKL, Subramanian S, Beebe MC, Hoover S, Royalty J, & Seeff LC (2013). Clinical costs of colorectal cancer screening in 5 federally funded demonstration programs. *Cancer*, 119(15), 2863–2869. doi:10.1002/cncr.28154 [PubMed: 23868481]

US Bureau of Labor Statistics. (2018). Consumer Price Index for All Urban Consumers: Medical Care (CPIMEDSL) Retrieved from <https://fred.stlouisfed.org/series/CPIMEDSL>. Accessed 12 February 2018.

Willan AR, & O'Brien BJ (1996). Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem. *Health Economics*, 5(4), 297–305. doi:10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T [PubMed: 8880166]

Highlights:

Implementing colorectal cancer screening across community health centers is complex
Intervention delivery costs and overall effectiveness vary across health centers Data
cleaning and training will likely be more expensive in smaller health centers Economic
effects of follow-on colonoscopies depend on success of fecal test referrals

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1.
 STOP CRC Activity Categories Per Clinic, by Health Center (2018 US\$)

Table 1.

STOP CRC Intervention Activities

<i>Data organization and management</i>	
	Updating claims data (e.g., historical colonoscopies)
	Initial EHR training
	Testing EHR tools
	Training of additional staff (e.g., MA)
	Execution of lab interface agreements
	Lab orders tracking
	Results pool tracking
<i>Staff training</i>	
	On-going training/meetings
	On-boarding of new staff
<i>Dissemination labo</i>	
	Adapting/approving mailed materials
	Mailing introductory letter
	Mailing FIT kits
	Mailing reminders
	In-clinic FIT kit distribution
<i>Dissemination non-labor</i>	
	<i>Introductory letters with envelope</i>
	<i>FIT kits</i>
	<i>Reminder letters</i>
<i>Program management</i>	
	Billing adjustments
	Conducting a PDSA
	Provider engagement meetings
<i>Test processing</i>	
	Processing of returned FITs
	Reimbursement for returns from insured
<i>Delivery support</i>	
	Responding to patient phone calls

EHR: electronic health record

MA: medical assistant

FIT: fecal immunochemical test

PDSA: plan-do-study-act

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

STOP CRC Outcomes

PRIMARY								
	USUAL CARE				INTERVENTION			
Health Center	N screened	Eligibles	Proportion		N screened	Eligibles	Proportion	12-month change
1	23	840	2.7%		123	606	20.3%	17.6%
2	498	4,260	11.7%		1,227	5,762	21.3%	9.6%
3	427	2,004	21.3%		403	1,761	22.9%	1.6%
4	221	3,246	6.8%		265	1,882	14.1%	7.3%
5	350	2,991	11.7%		101	2,352	4.3%	-7.4%
6	372	3,349	11.1%		647	5,262	12.3%	1.2%
7	214	2,401	8.9%		128	2,129	6.0%	-2.9%
8	145	968	15.0%		108	1,380	7.8%	-7.2%
<i>Total</i>	<i>2,146</i>	<i>20,059</i>	<i>10.7%</i>		<i>3,003</i>	<i>21,134</i>	<i>14.2%</i>	<i>3.5%</i>
Primary outcome: Proportion of persons completing a FIT within 12 months of eligibility for screening								
LAGGED								
	USUAL CARE				INTERVENTION			
Health Center	N screened	Eligibles	Proportion		N screened	Eligibles	Proportion	12-month change
1	23	674	3.4%		122	496	24.6%	21.2%
2	441	3,429	12.7%		1,065	4,359	23.3%	10.6%
3	344	1,571	21.9%		377	1,392	27.1%	5.2%
4	185	2,508	8.0%		209	1,284	15.7%	7.7%
5	345	1,827	18.9%		133	1,851	7.2%	-11.7%
6	297	2,146	13.7%		564	3,337	17.3%	3.6%
7	207	1,984	11.2%		173	1,874	9.2%	-2.0%
8	130	765	17.0%		135	1,170	11.6%	-5.4%
<i>Total</i>	<i>1,972</i>	<i>14,904</i>	<i>12.7%</i>		<i>2,778</i>	<i>15,763</i>	<i>17.5%</i>	<i>4.8%</i>

FIT: fecal immunochemical test

Table 3.

STOP CRC delivery costs and incremental cost-effectiveness ratios: primary dataset (95% CI)*

SYSTEM	HC1	HC2	HC3	HC4	HC5	HC6	HC7	HC8	TOTAL
Screening-eligible patients (SEP)									
Intervention	606	5,762	1,761	1,882	2,352	5,262	2,129	1,380	21,134
Usual care	840	4,260	2,004	3,246	2,991	3,349	2,401	968	20,059
Intervention delivery cost									
Total	\$10,171	\$110,035	\$28,363	\$30,147	\$26,434	\$54,557	\$28,430	\$16,860	\$304,997
Per SEP	\$16.78	\$19.10	\$16.11	\$16.02	\$11.24	\$10.37	\$13.35	\$12.22	\$14.43 (\$12.45–\$16.41)
Clinics (N)	1	3	1	2	1	2	1	2	13
# of completed FITs									
Intervention	123	1,227	403	265	101	647	128	108	3,002
Usual care	23	498	427	221	350	372	214	145	2,250
Incremental	100	729	-24	44	-249	275	-86	-37	752
Completed FITs per screening-eligible patient									
Intervention	0.20	0.21	0.23	0.14	0.04	0.12	0.06	0.08	0.14
Usual care	0.03	0.12	0.21	0.07	0.12	0.11	0.09	0.15	0.11
Incremental	0.18	0.10	0.02	0.07	-0.07	0.01	-0.03	-0.07	0.03 (-0.03–0.09)
Abnormal FITs									
Intervention	11	219	35	39	15	53	12	19	403
with CS	3	66	20	27	1	10	7	10	144
Usual care	1	110	18	21	122	41	15	25	353
with CS	0	52	7	7	64	16	5	9	160
Incr. abn. FITs	10	109	17	18	-107	12	-3	-6	50
Incr. abn. FITs w/ CS	3	14	13	20	-63	-6	2	1	-16
Incremental cost-effectiveness ratios									
Delivery cost / completed FITs	\$102	\$151	-\$1,182	\$685	-\$106	\$198	-\$331	-\$456	\$406
Delivery cost per SEP / completed FITs per SEP	\$96	\$199	\$1,021	\$220	-\$152	\$873	-\$460	-\$171	\$483 (\$458–\$511)
Delivery cost (w/ CS) / completed FITs	\$159	\$187	-\$2,209	\$1,547	\$374	\$157	-\$375	-\$507	\$365
Delivery cost (w/ CS) per SEP / completed FITs per SEP	\$149	\$184	\$1,967	\$538	\$385	\$413	-\$539	-\$116	\$409 (\$388–\$433)

HC: health center; FIT: fecal immunochemical test; CS: (follow-up) colonoscopy; CI: confidence interval

* Negative incremental ratios mean that the intervention was more expensive and less effective than usual care.

Table 4.

STOP CRC delivery costs and incremental cost-effectiveness ratios: lagged dataset (95% CI)*

SYSTEM	HC1	HC2	HC3	HC4	HC5	HC6	HC7	HC8	TOTAL
Screening-eligible patients (SEP)									
Intervention	496	4,359	1,392	1,284	1,851	3,337	1,874	1,170	15,763
Usual care	674	3,429	1,571	2,508	1,827	2,146	1,984	765	14,904
Intervention delivery cost									
Total	\$10,171	\$110,035	\$28,363	\$30,147	\$26,434	\$54,557	\$28,430	\$16,860	\$304,997
Per SEP	\$20.51	\$25.24	\$20.38	\$23.48	\$14.28	\$16.35	\$15.17	\$14.41	\$19.35 (\$16.58–\$22.12)
Clinics (N)	1	3	1	2	1	2	1	2	13
# of completed FITs									
Intervention	122	1,065	377	209	133	564	173	135	2,778
Usual care	23	441	344	185	345	297	207	130	1,972
Incremental	99	624	33	24	-212	267	-34	5	806
Completed FITs per screening-eligible patient									
Intervention	0.25	0.24	0.27	0.16	0.07	0.17	0.09	0.12	0.18
Usual care	0.03	0.13	0.22	0.07	0.19	0.14	0.10	0.17	0.13
Incremental	0.21	0.12	0.05	0.09	-0.12	0.03	-0.01	-0.05	0.04 (-0.03-0.11)
Abnormal FITs									
Intervention	10	178	32	27	29	51	18	29	374
with CS	4	63	16	20	10	9	6	8	136
Usual care	1	71	32	17	87	30	14	40	292
with CS	0	27	16	4	46	12	6	11	122
Incr. abn. FITs	9	107	0	10	-58	21	4	-11	82
Incr. abn. FITs w/ CS	4	36	0	16	-36	-3	0	-3	14
Incremental cost-effectiveness ratios									
Delivery cost / completed FITs	\$103	\$176	\$859	\$1,256	-\$125	\$204	-\$836	\$3,372	\$378
Delivery cost per SEP / completed FITs per SEP	\$97	\$218	\$393	\$264	-\$122	\$534	-\$1,262	-\$264	\$441 (\$426-\$456)
Delivery cost (w/ CS) / completed FITs	\$179	\$286	\$859	\$2,521	\$197	\$183	-\$836	\$2,234	\$411
Delivery cost (w/ CS) per SEP / completed FITs per SEP	\$169	\$326	\$441	\$562	\$199	\$355	-\$1,290	-\$2	\$460 (\$444-\$476)

HC: health center; FIT: fecal immunochemical test; CS: (follow-up) colonoscopy, CI: confidence interval

* Negative incremental ratios mean that the intervention was more expensive and less effective than usual care.